Abstract
Abstract
Background
Bronchiolitis is a major cause of hospitalization in infants, particularly in the first six months of life, with approximately 60–80% of admissions due to respiratory syncytial virus (RSV) infection. Currently, no prophylactic options are available for healthy infants. The present study aimed at describing the demographic, clinical, and epidemiological characteristics of infants hospitalized for bronchiolitis in the Apulia region of Italy in 2021.

Methods
From January to December 2021, data on children aged 0–12 months admitted for bronchiolitis in nine neonatal or pediatric units covering 61% of pediatric beds of hospitals in the Apulia region of Italy were analyzed. Demographic data, comorbidities, need for oxygen support, length of hospital stay, palivizumab administration, and outcomes were collected. For the purpose of the analysis, patients were divided into those aged 0–3 months and > 3 months. A multivariate logistic regression model was used to explore associations between the need for oxygen support and sex, age, comorbidities, history of prematurity, length of hospital stay, and palivizumab administration.

Results
This study included 349 children aged 0–12 months admitted for bronchiolitis, with a peak of hospitalization in November (7.4 cases/1,000 children). Of these patients, 70.5% were RSV positive, 80.2% were aged 0–3 months, and 73.1% required oxygen support. Moreover, 34.9% required observation in the sub-intensive care unit, and 12.9% in the intensive care unit. Of the infants who required intensive care, 96.9% were aged 0–3 months and 78.8% were born at term. Three patients required mechanical ventilation and one, who required Extra Corporeal Membrane Oxygenation, died. Children aged 0–3 months were more likely to show dyspnea, need oxygen support, and have a longer hospital stay.

Conclusions
The present study showed that almost all of the children who required intensive care support were aged ≤ 3 months and most were born at term. Therefore, this age group remains the highest risk group for severe bronchiolitis. Preventive measures such as single-dose monoclonal antibody immunoprophylaxis, and maternal and childhood vaccination against RSV, may reduce the high public health burden of bronchiolitis.
Topics

No keywords indexed for this article. Browse by subject →

References
38
[1]
Dalziel SR, Haskell L, O’Brien S, Borland ML, Plint AC, Babl FE, Oakley E, Bronchiolitis. Lancet. 2022 Jul 30;400(10349):392–406. doi: https://doi.org/10.1016/S0140-6736(22)01016-9. Epub 2022 Jul 1. PMID: 35785792. 10.1016/s0140-6736(22)01016-9
[2]
Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr. Trends in bronchiolitis hospitalizations in the United States, 2000–2009. Pediatrics. 2013 Jul;132(1):28–36. https://doi.org/10.1542/peds.2012-3877. Epub 2013 Jun 3. PMID: 23733801; PMCID: PMC3691534. 10.1542/peds.2012-3877
[3]
Fretzayas A, Moustaki M. Etiology and clinical features of viral bronchiolitis in infancy. World J Pediatr. 2017 Aug;13(4):293–9. https://doi.org/10.1007/s12519-017-0031-8. Epub 2017 May 4. PMID: 28470580; PMCID: PMC7090852. 10.1007/s12519-017-0031-8
[4]
Bont L, Checchia PA, Fauroux B, Figueras-Aloy J, Manzoni P, Paes B, Simões EA, Carbonell-Estrany X. Defining the epidemiology and burden of severe respiratory syncytial virus infection among Infants and Children in Western Countries. Infect Dis Ther. 2016 Sep;5(3):271–98. Epub 2016 Aug 1. PMID: 27480325; PMCID: PMC5019979. 10.1007/s40121-016-0123-0
[5]
Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017 Sep 2;390(10098):946–958. doi: https://doi.org/10.1016/S0140-6736(17)30938-8. Epub 2017 Jul 7. PMID: 28689664; PMCID: PMC5592248. 10.1016/s0140-6736(17)30938-8
[6]
Bohmwald K, Espinoza JA, Pulgar RA, Jara EL, Kalergis AM. Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus.Front Immunol. 2017 Nov27;8:1643. doi: https://doi.org/10.3389/fimmu.2017.01643. PMID: 29230219; PMCID: PMC5712212. 10.3389/fimmu.2017.01643
[7]
Efstathiou C, Abidi SH, Harker J, Stevenson NJ. Revisiting respiratory syncytial virus’s interaction with host immunity, towards novel therapeutics. Cell Mol Life Sci. 2020 Dec;77(24):5045–58. https://doi.org/10.1007/s00018-020-03557-0. Epub 2020 Jun 16. PMID: 32556372; PMCID: PMC7298439. 10.1007/s00018-020-03557-0
[8]
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young chil-dren: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: https://doi.org/10.1016/S0140-6736(10)60206-1. PMID: 20399493; PMCID: PMC2864404. 10.1016/s0140-6736(10)60206-1
[9]
Kuhdari P, Brosio F, Malaventura C, Stefanati A, Orsi A, Icardi G, Gabutti G. Human respiratory syncytial virus and hospitalization in young children in Italy. Ital J Pediatr. 2018 May 4;44(1):50. doi: https://doi.org/10.1186/s13052-018-0492-y. PMID: 29728106; PMCID: PMC5935991. 10.1186/s13052-018-0492-y
[10]
Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, Mejías A, Baraldi E, Pa-padopoulos NG, Nair H, Nunes MC, Kragten-Tabatabaie L, Heikkinen T, Greenough A, Stein RT, Manzoni P, Bont L, Martinón-Torres F. Respiratory Syncytial Virus Seasonality: A Global Overview. J Infect Dis. 2018 Apr 11;217(9):1356–1364. doi: https://doi.org/10.1093/infdis/jiy056. PMID: 29390105. 10.1093/infdis/jiy056
[11]
Berdah L, Romain AS, Rivière S, Schnuriger A, Perrier M, Carbajal R, Lorrot M, Guedj R, Corvol H. Retrospective ob-servational study of the influence of the COVID-19 outbreak on infants’ hospitalisation for acute bronchiolitis. BMJ Open. 2022 Oct 31;12(10):e059626. doi: https://doi.org/10.1136/bmjopen-2021-059626. PMID: 36316083; PMCID: PMC9627576. 10.1136/bmjopen-2021-059626
[12]
Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko M. Effect of Social Distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during Early 2020. Pediatr Infect Dis J. 2020;39:e423–7. 10.1097/inf.0000000000002845
[13]
Guedj R, Lorrot M, Lecarpentier T, Leger PL, Corvol H, Carbajal R. Infant bronchiolitis dramatically reduced during the second french COVID-19 outbreak. Acta Paediatr. 2021;110:1297–9. 10.1111/apa.15780
[14]
Rambaud J, Dauger S, Morin L, Bergounioux J, Leger PL, Carbajal R, Renolleau S, Guedj R. Bronchiolitis ad-missions to intensive care during COVID. Pediatrics. 2021;147:e2021050103. 10.1542/peds.2021-050103
[15]
Vittucci AC, Piccioni L, Coltella L, Ciarlitto C, Antilici L, Bozzola E, Midulla F, Palma P, Perno CF, Villani A. The disappearance of respiratory viruses in children during the COVID-19 pandemic. Int J Environ Res Public Health. 2021;18:9550. 10.3390/ijerph18189550
[16]
Curatola A, Lazzareschi I, Bersani G, Covino M, Gatto A, Chiaretti A. Impact of COVID-19 outbreak in acute bronchiolitis: lesson from a tertiary italian Emergency Department. Pediatr Pulmonol. 2021;56:2484–8. 10.1002/ppul.25442
[17]
Loconsole D, Centrone F, Rizzo C, Caselli D, Orlandi A, Cardinale F, Serio C, Giordano P, Lassandro G, Milella L, Fi-carella MT, Baldassarre ME, Laforgia N, Chironna M. Out-of-Season Epidemic of Respiratory Syncytial Virus during the COVID-19 Pandemic: The High Burden of Child Hospitalization in an Academic Hospital in Southern Italy in 2021. Children (Basel). 2022 Jun 8;9(6):848. doi: https://doi.org/10.3390/children9060848. PMID: 35740785; PMCID: PMC9221938. 10.3390/children9060848
[18]
Heikkilä P, Forma L, Korppi M. Hospitalisation costs for infant bronchiolitis are up to 20 times higher if intensive care is needed. Acta Paediatr. 2015 Mar;104(3):269–73. https://doi.org/10.1111/apa.12881. Epub 2015 Jan 30. PMID: 25431309. 10.1111/apa.12881
[19]
Bozzola E, Ciarlitto C, Guolo S, Brusco C, Cerone G, Antilici L, Schettini L, Piscitelli AL, Chiara Vittucci A, Cutrera R, Raponi M, Villani A. Respiratory Syncytial Virus Bronchiolitis in Infancy: The Acute Hospitalization Cost.Front Pediatr. 2021 Jan18;8:594898. doi: https://doi.org/10.3389/fped.2020.594898. PMID: 33537260; PMCID: PMC7848214. 10.3389/fped.2020.594898
[20]
Agenzia Italiana del Farmaco. Determina 2 Novembre 2017. Available online: https://www.gazzettaufficiale.it/eli/id/2017/11/09/17A07585/sg.2017 (accessed on 15 February 2022).
[21]
Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, Manzoni P, Boldrini A, Paolillo P, Di Fabio S et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital. J. Pe-diatr. 2015, 41,97. 10.1186/s13052-015-0203-x
[22]
Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceu-tical interventions on the future dynamics of endemic infections. Proc. Natl. Acad. Sci. USA 2020, 117, 30547–30553. 10.1073/pnas.2013182117
[23]
Barbati F, Moriondo M, Pisano L, Calistri E, Lodi L, Ricci S, Giovannini M, Canessa C, Indolfi G, Azzari C. Epidemiology of Respiratory Syncytial Virus-Related Hospitalization Over a 5-Year Period in Italy: Evaluation of Seasonality and Age Distribution Before Vaccine Introduction. Vaccines (Basel). 2020 Jan 4;8(1):15. doi: https://doi.org/10.3390/vaccines8010015. PMID: 31947976; PMCID: PMC7157234. 10.3390/vaccines8010015
[24]
Ramilo O, Mejias A. Measuring the Burden of RSV in children to precisely assess the impact of preventive strategies. Pediatrics. 2020 Jul;146(1):e20201727. https://doi.org/10.1542/peds.2020-1727. Epub 2020 Jun 16. PMID: 32546584. 10.1542/peds.2020-1727
[25]
Havdal LB, Bøås H, Bekkevold T, Kran AB, Rojahn AE, Størdal K, Debes S, Døllner H, Nordbø SA, Barstad B, Haarr E, Fernández LV, Nakstad B, Inchley C, Flem E. The burden of respiratory syncytial virus in children under 5 years of age in Norway. J Infect. 2022 Feb;84(2):205–15. Epub 2021 Dec 11. PMID: 34906596. 10.1016/j.jinf.2021.12.008
[26]
The Burden of Respiratory Syncytial Virus Infection in Young Children

Caroline Breese Hall, Geoffrey A. Weinberg, Marika K. Iwane et al.

New England Journal of Medicine 10.1056/nejmoa0804877
[27]
van Summeren JJGT, Rizzo C, Hooiveld M, Korevaar JC, Hendriksen JMT, Dückers MLA, Loconsole D, Chironna M, Bangert M, Demont C, Meijer A, Caini S, Pandolfi E, Paget J. Evaluation of a standardised protocol to measure the dis-ease burden of respiratory syncytial virus infection in young children in primary care. BMC Infect Dis. 2021 Jul 26;21(1):705. doi: https://doi.org/10.1186/s12879-021-06397-w. PMID: 34311699; PMCID: PMC8311415. 10.1186/s12879-021-06397-w
[28]
Kieffer A, Beuvelet M, Sardesai A, Musci R, Milev S, Roiz J, Lee JKH. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.J Infect Dis. 2022 Aug15;226(Suppl 2):S282-S292. doi: https://doi.org/10.1093/infdis/jiac216. PMID: 35968866; PMCID: PMC9377043. 10.1093/infdis/jiac216
[29]
Díez-Gandía E, Gómez-Álvarez C, López-Lacort M, Muñoz-Quiles C, Úbeda-Sansano I, Díez-Domingo J, Orrico-Sánchez A. ; Study collaborators. The impact of childhood RSV infection on children’s and parents’ quality of life: a prospective multicenter study in Spain. BMC Infect Dis. 2021 Sep 6;21(1):924. doi: https://doi.org/10.1186/s12879-021-06629-z. PMID: 34488668; PMCID: PMC8422742. 10.1186/s12879-021-06629-z
[30]
Ledbetter J, Brannman L, Wade SW, Gonzales T, Kong AM. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants. J Med Econ. 2020 Feb;23(2):139–147. doi: 10.1080/13696998.2019.1658592. Epub 2019 Sep 4. PMID: 31432723. 10.1080/13696998.2019.1658592
[31]
Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis

Shawn L. Ralston, Allan S. Lieberthal, H. Cody Meissner et al.

Pediatrics 10.1542/peds.2014-2742
[32]
IMpact-RSV. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998 Sep;102(3):531–7. PMID: 9724660. 10.1542/peds.102.3.531
[33]
Hodgson D, Koltai M, Krauer F, Flasche S, Jit M, Atkins KE. Optimal Respiratory Syncytial Virus intervention pro-grammes using Nirsevimab in England and Wales. Vaccine. 2022 Nov 22;40(49):7151–7157. doi: https://doi.org/10.1016/j.vaccine.2022.10.041. Epub 2022 Oct 31. PMID: 36328884. 10.1016/j.vaccine.2022.10.041
[34]
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T, MELODY Study Group. ;. Nirse-vimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837–846. doi: https://doi.org/10.1056/NEJMoa2110275. PMID: 35235726. 10.1056/nejmoa2110275
[35]
Scotta MC, Stein RT. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood. J Pediatr (Rio J). 2022 Nov 16:S0021-7557(22)00122-X. doi: https://doi.org/10.1016/j.jped.2022.10.004. Epub ahead of print. PMID: 36402228. 10.1016/j.jped.2022.10.004
[36]
American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Volume 134. Pediatrics: American Academy of Pediatrics Committee on Infectious Diseases; 2014. pp. 415–20.
[37]
World Health Organization. Global Influenza Programme - Respiratory Syncytial Virus Surveillance. Available online: https://www.who.int/teams/global-influenza-programme/global-respiratory-syncytial-virus-surveillance (accessed on 10 November 2022).
[38]
Broor S, Campbell H, Hirve S, Hague S, Jackson S, Moen A, Nair H, Palekar R, Rajatonirina S, Smith PG, Venter M, Wairagkar N, Zambon M, Ziegler T, Zhang W. Leveraging the global influenza surveillance and response system for global respiratory syncytial virus surveillance-opportunities and challenges. Influenza Other Respir Viruses. 2020 Nov;14(6):622–9. https://doi.org/10.1111/irv.12672. Epub 2019 Aug 24. PMID: 31444997; PMCID: PMC7578328. 10.1111/irv.12672
Metrics
15
Citations
38
References
Details
Published
Jun 06, 2023
Vol/Issue
49(1)
License
View
Cite This Article
Maria Elisabetta Baldassarre, Daniela Loconsole, Francesca Centrone, et al. (2023). Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?. Italian Journal of Pediatrics, 49(1). https://doi.org/10.1186/s13052-023-01455-2
Related

You May Also Like